Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Apr 29, 2019: Results from the Japanese Phase III study
Press releases — page 8
Results from the Japanese Phase III study
April 29, 2019
First expansion cohort for MATINS trial part 2
April 11, 2019
Notice of Results
April 5, 2019
Results of the Placing and Subscription
March 28, 2019
Result of Placing and Issue Price
March 26, 2019
New data published by Clinical Cancer Research
February 13, 2019
Traumakine update - YODA results
December 19, 2018
First patient dosed in phase I/II MATINS study
December 14, 2018
Patient subgroup identified from INTEREST trial
December 5, 2018
Faron receives CTA approval for Clevegen
December 3, 2018
PDMR Dealings
November 6, 2018
INTEREST trial update presented at ESICM
October 22, 2018
Director/PDMR Shareholding
September 18, 2018
Faron announces CTA filing for Clevegen
September 17, 2018
Interim Results
September 13, 2018
New data published on Clever-1 function
September 12, 2018
Clevegen successful toxicity studies
June 28, 2018
Biomarker analysis of Phase III INTEREST trial
June 14, 2018
AGM Statement
May 31, 2018
PDMR Shareholding
May 16, 2018
Update on the Phase III INTEREST trial
May 11, 2018
Top line data from the Phase III INTEREST trial
May 8, 2018
Notice of Full Year Results
March 21, 2018
Results of Placing & Issue of Equity
February 21, 2018
Proposed Placing to raise up to £15m
February 16, 2018
Second Traumakine manufacturing site established
February 5, 2018
Faron Announces Clevegen Grant of European Patent
February 1, 2018
FDA grants Fast Track Designation for Traumakine®
January 29, 2018
FDA approval of Faron's Traumakine® IND
January 24, 2018
INFORAAA trial receives recommendation from IDMC
December 19, 2017
Faron announces R&D Day in February 2018
December 14, 2017
Recruitment completed in Traumakine INTEREST Trial
December 11, 2017
Appointment of Chief Commercial Officer
December 1, 2017
Issue of Equity & PDMR Shareholding
October 11, 2017
Result of Placing & Subscription & Issue of Equity
October 9, 2017
Proposed Placing and Subscription
October 5, 2017
Traumakine Receives PIM Designation from MHRA
October 2, 2017
Directors Dealings
September 11, 2017
FDA advises Faron to proceed directly to BLA
September 4, 2017
Update on INTEREST Phase III Study from IDMC
August 4, 2017
Exercise of Warrants and Options
June 1, 2017
Exercise of Warrants
April 27, 2017
Director's dealings
April 26, 2017
Proposed Board Changes
April 19, 2017
Purchase of Shares
April 18, 2017
Final Results 2016
March 29, 2017
First Patient Recruited in Phase II RAAA Study
February 20, 2017
Faron update for 2017
February 9, 2017
Notification of Major Interest in Shares
December 9, 2016
New Application Accepted by Finnish Patent Office
October 31, 2016